Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy

Cui Jiang(Liaoning Cancer Hospital & Institute), Tao Sun(Ningxia Medical University), Lei Jiang(Second Military Medical University), Zhichao Gao(Liaoning Cancer Hospital & Institute), Na Li(Educational Department of Liaoning Province), Xiaorui Li(Shandong University of Traditional Chinese Medicine), Shuo Wu(Tropical Crops Genetic Resources Institute), Yangyang Duan(Liaoning Cancer Hospital & Institute)
PeerJ
September 3, 2019
10.7717/peerj.7515
Cited by 18

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Genetics of rheumatoid arthritis contributes to biology and drug discovery
|Nature|2013|2.5k
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369
Magnesium Levels in Drinking Water and Coronary Heart Disease Mortality Risk: A Meta-Analysis
|Nutrients|2016|100
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
|Future Oncology|2021|93